Skip to main content

Jean-Paul Clozel

Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the business will launch under the name Idorsia. When the deal was originally announced, Clozel had pencilled in NewCo for his next venture.


Share this article

View all news

Sign up to receive our newsletter in your inbox.